An Open-label, Non-randomized, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1238097 in Subjects With Advanced Malignancies

Trial Profile

An Open-label, Non-randomized, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1238097 in Subjects With Advanced Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs BAY 1238097 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man
  • Sponsors Bayer
  • Most Recent Events

    • 02 Dec 2016 Results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 10 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 27 Jan 2016 Planned End Date changed from 1 Aug 2017 to 1 Feb 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top